FRA/VX1 (FRA/VX1)

Frankfurt Stock Exchange: FRA/VX1 · EUR

€469

+10.41 (+2.3%)· Recorded snapshot

Market cap	118.5B
Revenue (ttm)	11B
Net income (ttm)	3.9B
EPS (ttm)	€15.4
P/E (trailing)	30.3x
P/E (forward)	28.8x
Volume	10

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 11B
Net income (ttm): 3.9B
EPS (ttm): €15.4
P/E (trailing): 30.3x
P/E (forward): 28.8x
Market cap: 118.5B

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E28.8

P25 n/aP50 n/aP75 n/a

Trailing P/E30.3

P25 n/aP50 n/aP75 n/a

ROE23.5

P25 n/aP50 n/aP75 n/a

ROIC28.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All FRA/VX1 indicators

Market & fundamental data

Available fields

243

Groups with data

Currency

USD

Showing 243 of 243 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	EUR
Country	United States
Country code	DE
Earnings date	2026-11-02
Employees	6,400
Employees change	700
Employees growth	12.96%
Enterprise value	EUR 108.1B
Exchange	Frankfurt Stock Exchange
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-10
Fiscal year end	December
Founded	1989
Industry	Biotechnology
Is primary listing	No
ISIN number	US92532F1003
Last earnings date	2026-08-03
Last refreshed	2026-10-28
Market cap	EUR 118.5B
Next earnings date	2026-11-02
Price	EUR 468.80
Price currency	EUR
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-27
Symbol	fra/VX1
Website	https://www.vrtx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (10Y)	50.03x
Average P/E ratio (3Y)	28.04x
Average P/E ratio (5Y)	26.01x
Earnings yield	3.3%
EV/Earnings	28.02x
EV/EBIT	24.52x
EV/EBITDA	22.32x
EV/FCF	32.52x
EV/Sales	9.57x
FCF / EV yield	3.08%
FCF yield	2.8%
Forward P/E	28.82x
Graham number	155.09593
Graham upside	-66.92%
Lynch fair value	EUR 262.39
Lynch upside	-44.03%
P/(FCF - SBC) ratio	43.58x
P/(OCF - SBC) ratio	37.57x
P/B ratio	6.69x
P/E ratio	30.35x
P/FCF ratio	35.67x
P/OCF ratio	31.54x
P/S ratio	10.76x
Price / tangible book value	7.22x
Price/EBITDA ratio	26.55x
Sector forward P/E	14.8x
Sector P/E	39.91x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	39%
EBITDA margin	40.52%
Effective tax rate	16.48%
FCF margin	29.36%
Gross margin	54.96%
Operating margin	39%
Pretax margin	41.9%
Profit margin	35%
Profit per employee	EUR 602,480
Profitable quarters	8
Profitable years	1
Revenue per employee	EUR 1.7M
ROA	11.93%
ROA (5Y)	14.82%
ROCE	20.9%
ROE	23.54%
ROE (5Y)	19%
ROIC	28.8%
ROIC (5Y)	37.75%
SBC / revenue	5.47%
Tax / revenue	6.91%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	22.12%
EPS growth (Q)	8.02%
EPS growth (QoQ)	7.21%
EPS growth 3Y	9.92%
EPS growth 5Y	17.77%
EPS growth quarters	5
EPS growth years	1
FCF growth	8.47%
FCF growth (Q)	9.25%
FCF growth (QoQ)	-21.74%
FCF growth 3Y	-0.71%
FCF growth 5Y	16.39%
Gross profit growth	15.3%
Gross profit growth (Q)	17.23%
Gross profit growth 3Y	8.01%
Gross profit growth 5Y	11.52%
Net income growth	21.1%
Net income growth (Q)	6.48%
Net income growth (QoQ)	6.63%
Net income growth 3Y	9.4%
Net income growth 5Y	17.2%
Net income growth quarters	5
Net income growth years	1
OCF growth	11.61%
OCF growth (Q)	4.87%
OCF growth (QoQ)	-21.2%
OCF growth 3Y	1.81%
OCF growth 5Y	15.15%
Operating income growth	10.85%
Operating income growth (Q)	9.92%
Operating income growth 3Y	3.16%
Operating income growth 5Y	8.75%
Revenue growth	10.23%
Revenue growth (Q)	12.45%
Revenue growth (QoQ)	11.62%
Revenue growth 10Y	23.24%
Revenue growth 3Y	9.81%
Revenue growth 5Y	13.5%
Revenue growth quarters	33
Revenue growth years	11

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	EUR -434.8M
Depreciation and amortization	EUR 171.6M
EBIT	EUR 4.3B
EBITDA	EUR 4.5B
EPS	EUR 15.45
Financing cash flow	EUR -1.9B
Free cash flow	EUR 3.3B
Free cash flow minus SBC	EUR 2.7B
Gross profit	EUR 6.1B
Income taxes	EUR 760.9M
Investing cash flow	EUR -772.7M
Net borrowing	EUR -4.9M
Net cash flow	EUR 1B
Net income	EUR 3.9B
Operating cash flow minus SBC	EUR 3.2B
Operating income	EUR 4.3B
Revenue	EUR 11B
Stock-based compensation	EUR 603.2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	11.58
Book value per share	EUR 69.96
Debt / EBITDA	0.37
Debt / equity	0.1
Debt / FCF	0.52
Goodwill	EUR 978.2M
Interest coverage	369.14
Long-term assets	EUR 12.7B
Long-term liabilities	EUR 2.7B
Net cash (debt)	EUR 10.2B
Net cash / market cap	8.61%
Net cash growth	11.07%
Net debt / EBITDA	-2.29
Net debt / equity	-0.58
Net debt / FCF	-3.07
Piotroski F-Score	5
Property, plant and equipment	EUR 3B
Shareholders' equity	EUR 17.7B
Tangible book value	EUR 16.4B
Tangible book value per share	EUR 64.77
Total assets	EUR 24B
Total cash	EUR 6.9B
Total debt	EUR 1.7B
Total liabilities	EUR 6.3B

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.49
Current assets	EUR 11.3B
Current liabilities	EUR 3.5B
Current ratio	3.19
Inventory turnover	3.47
Net working capital	EUR 659.5M
Quick ratio	2.54
Working capital	EUR 7.5B
Working capital turnover	1.48

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	0.85%
Shareholder yield	0.85%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	553.96%
10Y return CAGR	20.66%
10Y total return	553.96%
150-day SMA	EUR 418.11
15Y price change	1,433.28%
15Y return CAGR	19.96%
15Y total return	1,433.28%
1D price change	2.27%
1M price change	1.71%
1M total return	1.71%
1W price change	5.31%
1W total return	5.31%
1Y price change	29.08%
1Y return CAGR	29.1%
1Y total return	29.08%
20-day SMA	EUR 454.83
200-day SMA	EUR 413.76
3M price change	13.03%
3M total return	13.03%
3Y price change	37.12%
3Y return CAGR	11.09%
3Y total return	37.12%
50-day SMA	EUR 458.24
50-day SMA vs 200-day SMA	50over200
52-week high	EUR 479.20
52-week high date	2026-09-03
52-week low	EUR 352.85
52-week low date	2025-11-04
5Y price change	191.98%
5Y return CAGR	23.9%
5Y total return	191.98%
6M price change	27.7%
6M total return	27.7%
All-time high	EUR 487.00
All-time high date	2024-11-11
All-time low	EUR 20.03
All-time low date	2011-11-25
Average true range (ATR)	EUR 7.72
Average volume	22.6
Change from 52-week high	-2.17%
Change from 52-week low	32.86%
Change from all-time high	-3.74%
Change from all-time low	2,241.07%
Change from open	2.15%
Day's gap	0.12%
Dollar volume	EUR 4,688
High price	EUR 468.80
Low price	EUR 458.95
Monthly RSI	61.05
Open price	EUR 458.95
Position in 52-week range	100%
Previous close	EUR 458.40
Price vs 150-day SMA	12.12%
Price vs 20-day SMA	3.07%
Price vs 200-day SMA	13.3%
Price vs 50-day SMA	2.31%
Relative volume	0.44
RSI	58.12
Sharpe ratio	0.88
Sharpe ratio (3Y)	0.34
Sharpe ratio (5Y)	0.7
Sortino ratio	1.74
Sortino ratio (3Y)	0.65
Sortino ratio (5Y)	1.2
Volume	10
Weekly RSI	60.73
YTD price change	20.48%
YTD total return	20.48%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	252.7M
Shares change (QoQ)	-0.43%
Shares change (YoY)	-0.85%
Shares held by insiders	0.2%
Shares held by institutions	97.11%
Short ratio	3.6 days

Deeper analysis on FRA/VX1

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this FRA/VX1 report

Is a complete FRA/VX1 research report available?

No complete published report is available for fra/VX1 (FRA/VX1) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

FRA/VX1 (FRA/VX1)

Price

Financial snapshot

Fair-value bridge

Latest news · FRA/VX1

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All FRA/VX1 indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on FRA/VX1

Frequently asked questions